Evidence map›Paper›PMID 35224054›Full record

ArticleFrontiers in cardiovascular medicine2022

RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study.

Eleonora Riccio, Ivana Capuano, Pasquale Buonanno, Michele Andreucci, Michele Provenzano, Maria Amicone, Manuela Rizzo, Antonio Pisani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Nutrients · 2022
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Eleonora RiccioInstitute for Biomedical Research and Innovation, National Research Council of Italy, Palermo, Italy.
Ivana CapuanoDepartment of Public Health, Chair of Nephrology, University Federico II of Naples, Campania, Italy.
Pasquale BuonannoDepartment of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy.
Michele AndreucciDepartment of Medical and Surgical Sciences-Renal Unit, "Magna Graecia" University, Catanzaro, Italy.
Michele ProvenzanoDepartment of Medical and Surgical Sciences-Renal Unit, "Magna Graecia" University, Catanzaro, Italy.
Maria AmiconeDepartment of Public Health, Chair of Nephrology, University Federico II of Naples, Campania, Italy.
Manuela RizzoDepartment of Public Health, Chair of Nephrology, University Federico II of Naples, Campania, Italy.
Antonio PisaniDepartment of Public Health, Chair of Nephrology, University Federico II of Naples, Campania, Italy.
Federico II University Hospital · ITMagna Graecia University · ITInstitute for Biomedical Research and Innovation · ITUniversity of Naples Federico II · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperkalemia is common in patients treated with renin-angiotensin-aldosterone system inhibitors (RAASis), and it represents the main cause of the large gap reported between guideline recommendations and real-world practice in chronic kidney disease (CKD). We conducted a CKD-population-based restrospective study to determine the prevalence of patients with CKD treated with RAASis, incidence of hyperkalemia in patients with CKD treated with RAASis, and proportion of patients with RAASi medication change after experiencing incident hyperkalemia. Among 809 patients with CKD analyzed, 556 (68.7%) were treated with RAASis, and RAASi prescription was greater in stages 2-4 of CKD. Hyperkalemia occurred in 9.2% of RAASi-treated patients, and the adjusted rate of hyperkalemia among patients with stage 4-5 CKD was 3-fold higher compared with patients with eGFR > 60 ml/min/1.73 m

Indexed as

chronic kidney diseasehyperkalemiahypertensionprevalenceRAAS inhibitor

Identifiers

PMID35224054
PMCPMC8874323
OpenAlexW4211082853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.